KR102736980B1 - 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도 - Google Patents

면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도 Download PDF

Info

Publication number
KR102736980B1
KR102736980B1 KR1020177035003A KR20177035003A KR102736980B1 KR 102736980 B1 KR102736980 B1 KR 102736980B1 KR 1020177035003 A KR1020177035003 A KR 1020177035003A KR 20177035003 A KR20177035003 A KR 20177035003A KR 102736980 B1 KR102736980 B1 KR 102736980B1
Authority
KR
South Korea
Prior art keywords
polypeptide
acid sequence
nucleic acid
cholesterol
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035003A
Other languages
English (en)
Korean (ko)
Other versions
KR20180011130A (ko
Inventor
클라라 벨저
보스 빌럼 마인데르트 데
패트리스 다니엘 카니
Original Assignee
바게닝겐 유니버시테이트
위니베르시트카솔리끄드루뱅
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바게닝겐 유니버시테이트, 위니베르시트카솔리끄드루뱅 filed Critical 바게닝겐 유니버시테이트
Publication of KR20180011130A publication Critical patent/KR20180011130A/ko
Application granted granted Critical
Publication of KR102736980B1 publication Critical patent/KR102736980B1/ko
Assigned to 어드밴스드 마이크로바이옴므 인터벤션즈 비.브이. reassignment 어드밴스드 마이크로바이옴므 인터벤션즈 비.브이. 권리의 전부이전등록 Assignors: 바게닝겐 유니버시테이트, 위니베르시트카솔리끄드루뱅
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177035003A 2015-05-06 2016-05-04 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도 Active KR102736980B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
EP15166598.1 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (2)

Publication Number Publication Date
KR20180011130A KR20180011130A (ko) 2018-01-31
KR102736980B1 true KR102736980B1 (ko) 2024-12-02

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035003A Active KR102736980B1 (ko) 2015-05-06 2016-05-04 면역 신호전달 초래 및/또는 창자 장벽 기능에 영향 및/또는 대사 상태를 조절하기 위한 폴리펩티드의 용도

Country Status (14)

Country Link
US (2) US10738089B2 (enExample)
EP (1) EP3292135B1 (enExample)
JP (1) JP6894382B2 (enExample)
KR (1) KR102736980B1 (enExample)
CN (1) CN107980043B (enExample)
AU (2) AU2016257315A1 (enExample)
DK (1) DK3292135T3 (enExample)
EA (1) EA201700507A1 (enExample)
ES (1) ES2934138T3 (enExample)
HK (1) HK1252412A1 (enExample)
IL (1) IL255405B (enExample)
MX (1) MX390092B (enExample)
PL (1) PL3292135T3 (enExample)
WO (1) WO2016177797A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
DK3347030T3 (da) * 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
WO2018165338A2 (en) * 2017-03-07 2018-09-13 uBiome, Inc. Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
WO2021139766A1 (en) * 2020-01-10 2021-07-15 Huang Chih Hung Peptide interacting with toll-like receptor 2 and the composition comprising the same
WO2021194281A1 (ko) 2020-03-25 2021-09-30 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
WO2022002660A1 (en) 2020-07-01 2022-01-06 Wageningen Universiteit Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
DE60229508D1 (de) * 2001-02-28 2008-12-04 Nat Inst Of Advanced Ind Scien Drosophila-stamm, der in diesen übertragene(s) bradeion-gen(e) enthält
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7812121B2 (en) 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
US8784798B2 (en) 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
CN103154670B (zh) 2010-10-20 2016-02-24 皇家飞利浦电子股份有限公司 用于识别电气网络中的耗电器的分解装置和分解方法
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
DK3347030T3 (da) 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mark W.J. van Passel et al., ‘The Genome of Akkermansia muciniphila, a Dedicated Intestinal Mucin Degrader, and Its Use in Exploring Intestinal Metagenomes’, PLoS ONE, Vol. 6, Issue. 3, 2011.03.*

Also Published As

Publication number Publication date
PL3292135T3 (pl) 2023-01-02
CN107980043A (zh) 2018-05-01
WO2016177797A1 (en) 2016-11-10
ES2934138T3 (es) 2023-02-17
IL255405B (en) 2022-01-01
DK3292135T3 (da) 2022-10-31
US20210147489A1 (en) 2021-05-20
EA201700507A1 (ru) 2018-05-31
CN107980043B (zh) 2021-09-24
HK1252412A1 (zh) 2019-05-24
US11466057B2 (en) 2022-10-11
EP3292135A1 (en) 2018-03-14
US10738089B2 (en) 2020-08-11
AU2016257315A1 (en) 2017-11-23
AU2020267210A1 (en) 2020-12-17
MX390092B (es) 2025-03-11
KR20180011130A (ko) 2018-01-31
IL255405A0 (en) 2017-12-31
JP2018515502A (ja) 2018-06-14
CA2984985A1 (en) 2016-11-10
AU2020267210B2 (en) 2023-10-12
JP6894382B2 (ja) 2021-06-30
NZ737765A (en) 2024-08-30
MX2017014111A (es) 2018-02-26
EP3292135B1 (en) 2022-09-21
BR112017023751A2 (pt) 2018-07-31
US20180265554A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
AU2020267210B2 (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
JP2018515502A5 (enExample)
JP5871911B2 (ja) 治療用ペプチドの送達のための組成物および方法
Levit et al. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
KR102469701B1 (ko) 점막부착성 미생물
JP2022502067A (ja) アッカーマンシアムシニフィラ菌株およびその用途
KR102028771B1 (ko) 변형된 그람 양성 박테리아 및 그 사용 방법
EP4438049A1 (en) Genetically modified microorganism and use thereof
Zhang et al. Surface-displayed Amuc_1100 from Akkermansia muciniphila on Lactococcus lactis ZHY1 improves hepatic steatosis and intestinal health in high-fat-fed zebrafish
AU2018205999B2 (en) Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
JP2023554676A (ja) がん治療のためのａｍｕｃ＿１１００と免疫チェックポイント調節剤との併用療法
US20230265131A1 (en) Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
CN102181437B (zh) 猪脂联素球状结构域蛋白gAd基因及其编码的蛋白和应用
CA2984985C (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
EA040421B1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
BR112017023751B1 (pt) Uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular
US20220280580A1 (en) Lactococcal expression of il-35 for treatment of disease
Matsueda et al. Efficacy and safety of acotiamide (Z-338) administered orally for 4-weeks in patients with functional dyspepsia: results from a randomized, double-blind, placebo-controlled phase III trial in Japan
Carvalho et al. Cytosolic Flagellin Receptor NLRC4 Plays a Key Role in Host Defense Against Orally Administered Inflammation-Associated Bacteria
KR20140067711A (ko) M 세포 특이 표적 펩타이드 cks9 서열이 도입되어 t세포 성장인자 단백질을 분비하는 신규한 형질전환 유산균 및 그의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301